Merit Medical Systems Inc. has entered into a definitive agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical, Inc. The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions. The addition of the C2 CryoBalloon technology is aimed at expanding Merit's endoscopy portfolio, particularly in the treatment of Barrett's esophagus and other gastrointestinal disorders. The acquisition is projected to contribute approximately $6 million to $8 million in revenue in 2026 and is initially expected to be dilutive to GAAP net income and earnings per share, with accretion anticipated in subsequent periods.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000050), on October 17, 2025, and is solely responsible for the information contained therein.